AtriCure, Inc.

NASDAQ:ATRC

Medical - Instruments & Supplies

Healthcare
$55.45 +3.52%

+$0.96 today

Market cap
$2.82B
Beta
1.26
P/E (TTM)
-295.5
EPS (TTM)
-$0.10
52W Low $25.36High $43.18

Volume 0.60M

Average 0.77M

ATRC EBITDA Margin

EBITDA as a percentage of revenue.

AtriCure, Inc.NASDAQ: ATRC

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 9.0%

EBITDA Margin was 9.0% in Q2 FY2026, up 8.4 pp from a year earlier. On a trailing-twelve-month basis it was 6.6%, up 8.5 pp year over year. Over 3 fiscal years it widened by 12.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 6.9% for the fiscal year ending Dec 2026, up from 3.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
9.0%+4.0 pp QoQ
Last fiscal yearDec 2025
3.0%+7.0 pp YoY
LTMJun 2026
6.6%+8.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.4 pp-3.1 pp-11.5 pp
1 year+7.0 pp+3.8 pp-3.2 pp
3 years+12.0 pp+7.4 pp-4.6 pp
5 years+7.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.0%
Year-over-year change
+7.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ATRC compares with its peers on the latest reported figures

  • ATRC's LTM Jun 2026 EBITDA Margin of 6.6% is the lowest of the 5 companies compared; the peer median is 25.8%.
  • Its year-over-year change of +8.5 pp is the 2nd highest of 5, against a peer median of +1.1 pp.
  • Over three fiscal years its change of +12.0 pp compares with a peer median of -6.6 pp.
ATRC Competitors Peer median
EBITDA Margin for ATRC and competitors
Company Period LTM level YoY 3-year change
BSXBoston Scientific CorporationLTM Jun 202627.6% +2.2 pp+3.8 pp
MDTMedtronic plcLTM Jul 202627.3% +0.0 pp-0.9 pp
EWEdwards Lifesciences CorporationLTM Jun 202624.3% -7.1 pp-12.4 pp
LIVNLivaNova PLCLTM Sep 202614.0% +20.0 pp-12.4 pp
ATRCAtriCure, Inc.LTM Jun 20266.6% +8.5 pp+12.0 pp
Peer median (excluding ATRC) 25.8%+1.1 pp-6.6 pp

Competitors are the stored peer set for ATRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue274.33M330.38M399.25M465.31M534.53M
Cost of Revenue68.47M84.44M98.88M117.78M136.79M
Gross Profit205.86M245.94M300.37M347.52M397.74M
Gross Margin75.0%74.4%75.2%74.7%74.4%
Research & Development48.51M57.34M73.92M96.18M90.17M
Selling, General & Admin204.65M231.27M253.14M291.36M311.02M
Operating Expenses150.66M288.61M327.05M387.54M401.19M
Depreciation & Amortization10.44M11.71M14.81M18.73M20.53M
EBITDA65.75M(29.5M)(8.11M)(18.53M)16.25M
EBITDA Margin24.0%-8.9%-2.0%-4.0%3.0%
Operating Income55.21M(42.67M)(26.68M)(40.01M)(3.45M)
Operating Margin20.1%-12.9%-6.7%-8.6%-0.6%
Interest Income466K1.99M3.79M4.43M4.48M
Interest Expense4.92M4.99M6.93M6.41M5.88M
Other Income / Expenses(4.82M)(3.53M)(3.16M)(3.66M)(6.72M)
Income Before Tax50.39M(46.2M)(29.85M)(43.67M)(10.16M)
Pre-Tax Margin18.4%-14.0%-7.5%-9.4%-1.9%
Income Tax Expense188K268K591K1.02M1.29M
Net Income50.2M(46.47M)(30.44M)(44.7M)(11.45M)
Net Margin18.3%-14.1%-7.6%-9.6%-2.1%
EPS (Basic)1.11(1.02)(0.66)(0.95)(0.24)
EPS (Diluted)1.09(1.02)(0.66)(0.95)(0.24)
Weighted Avg Shares45.07M45.74M46.31M46.97M47.75M
Weighted Avg Shares (Diluted)46.04M45.74M46.31M46.97M47.75M

AtriCure, Inc.

NASDAQ:ATRC

Intrinsic Alpha fair value

Locked

Current Price

$55.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.